布加综合征患者接受直接口服抗凝药治疗的结果:一项奥地利多中心研究
该回顾性多中心研究评估了47例奥地利布加综合征患者使用直接口服抗凝药(DOAC)与维生素K拮抗剂的安全性和临床结局。中位随访82.5个月,22例(46.8%)患者接受DOAC治疗,完全缓解或维持14例(63.6%),发生4例大出血(18.2%),5年无移植生存率91.6%。作者认为DOAC似有效安全,但需更大前瞻性研究证实。
要点
- 47例布加综合征患者中22例(46.8%)接受DOAC治疗,中位治疗24.4个月
- DOAC治疗期间4例(18.2%)发生大自发性出血,发生率8.8/100患者年
- DOAC治疗患者完全缓解或维持14例(63.6%),5年无移植生存率91.6%
核心结论
- DOAC似对布加综合征患者长期抗凝有效且安全,但需更大前瞻性研究证实。
研究设计与样本
- 回顾性评估47例在6家奥地利中心治疗的布加综合征患者中DOAC与维生素K拮抗剂的安全性和相关临床结局。
主要发现
- 研究纳入时平均年龄37.9±14.0岁,平均终末期肝病模型评分13.1±5.1。
- 63.8%(n=30)患者有失代偿性肝病,87.2%(n=41)有门静脉高压临床体征。
- 中位随访82.5(四分位距43.1-121.8)个月,43例(91.5%)接受单纯抗凝或介入治疗后抗凝,包括22例(46.8%)接受DOAC(依度沙班10例、阿哌沙班4例、利伐沙班3例、达比加群3例、序贯使用多于一种DOAC 2例),中位治疗24.4(四分位距5.7-35.1)个月。
- 72.7%(16/22)患者从低分子肝素(n=12)或维生素K拮抗剂(n=4)在病情稳定或改善后转换为DOAC,27.3%(6/22)患者初始即接受DOAC治疗。
- 22例中14例(63.6%)达到或维持完全缓解(欧洲肝病学会标准),2例持续缓解,6例疾病进展(包括2例肝细胞癌)。
关键数值与推荐
- 完全缓解采用欧洲肝病学会标准评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Direct oral anticoagulants (DOACs) may simplify management of Budd-Chiari syndrome (BCS). Here, we report our experience with off-label use of DOACs for anticoagulation in BCS. METHODS: The safety of DOAC vs vitamin K antagonist treatment as well as associated clinical outcomes were retrospectively assessed in 47 BCS patients treated at 6 Austrian centers. RESULTS: Mean age at study inclusion was 37.9 ± 14.0 years and mean Model for End-Stage Liver Disease was 13.1 ± 5.1. Overall, 63.8% (n = 30) of patients had decompensated liver disease, and 87.2% (n = 41) showed clinical signs of portal hypertension. During a median follow-up of 82.5 (interquartile range, 43.1-121.8) months, 43 (91.5%) patients received anticoagulation alone or following interventional treatment, including 22 (46.8%) patients treated with DOACs (edoxaban: 10, apixaban: 4, rivaroxaban: 3, dabigatran: 3, more than one DOAC sequentially: 2) for a median of 24.4 (interquartile range, 5.7-35.1) months. While 72.7% (n = 16 of 22) of patients were switched from low-molecular-weight heparin (n = 12) or vitamin K antagonist (n = 4) to DOAC after disease stabilization or improvement, 27.3% (n = 6 of 22) of BCS patients were initially treated with DOAC. Complete response (European Association for the Study of the Liver criteria) was achieved or maintained in 14 (63.6%) of 22 patients, with ongoing response in 2 patients, while disease progressed in 6 patients (including 2 patients with hepatocellular carcinoma). Four major spontaneous bleedings (18.2%; incidence rate 8.8 per 100 patient-years; n = 2 upper gastrointestinal bleeding, n = 1 lower gastrointestinal bleeding, n = 1 hepatocellular carcinoma rupture), 7 minor bleedings, and 1 major procedure-related bleeding (4.5%; 2.2 per 100 patient-years) occurred during DOAC therapy. Overall transplant-free survival was 91.6% at 5 years. CONCLUSIONS: DOACs seem to be effective and safe for long-term anticoagulation in patients with BCS, but confirmation by larger prospective studies is needed.
引用
- Semmler G, Lindorfer A, Schäfer B, et al. Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study. Clin Gastroenterol Hepatol. 2022. PMID: 35533994. doi:10.1016/j.cgh.2022.04.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。